Jul. 3 at 5:42 PM
$BMEA
with BMEA trading at
$1.41, a "shorted-out float" defines a severe market bottleneck. Over 23.5% of BMEA’s 67.1M float is sold short with an extreme Days to Cover (DTC) of 12.5 days. When clinical catalysts (e.g., Q3 2026 BMF-650 weight-loss data) drop, shorts are forced to cover. Normal supply/demand is "short-circuited" as buying demand instantly eclipses the available liquid float, triggering a parabolic squeeze.
Historically, before the June 6, 2024 FDA clinical hold on BMF-219, BMEA consolidated in a clear channel. The upper boundary of this pre-hold trading channel was
$14.00 (anchored by JPMorgan’s April 2024 target, with a
$10.00 floor). The
$3.70 Juice Target on today’s chart is not a full valuation recovery, but a technical play to partially fill the post-hold gap. Hitting
$3.70 merely tests the post-crash floor, leaving substantial fundamental upside relative to the original
$14.00 pre-hold boundary.
